United States-based pharma giant Johnson and Johnson (J&J) has sought approval for clinical trial of its single-shot Covid-19 vaccine on adolescents aged 12-17 years in India.
The single-shot Covid vaccine developed by Johnson and Johnson has shown 85 per cent efficacy in preventing severe Covid-19 disease in phase 3 clinical trials.
"Johnson & Johnson is committed to facilitating global equitable access to its COVID-19 vaccine and recognize the unmet needs of children. On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12 – 17 years," Johnson & Johnson India spokesperson was quoted in a Economic Times report as saying.
Earlier this month, the single shot vaccine of J&J became the second COVID-19 vaccine which has been granted Emergency Use Authorisation (EUA) through the fast-track approval route by the Drug Controller General of India.
J&J has partnered with Indian vaccine maker Biological E Ltd for supply and manufacturing of its Covid-19 vaccine shot in the country.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.